Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 5871-5880 Newer>

The Motley Fool February 17, 2005 Jeff Hwang	Wal-Mart: $10 Billion Saved The retailer posts solid fourth-quarter earnings and breaks $10 billion in annual earnings for the first time.
The Motley Fool February 17, 2005 W.D. Crotty	Coke's a Value Stock Coca-Cola management expresses disappointment, but signs point to fizzier times ahead. With improving margins, and with Coke selling for 20.3 times free cash flow to enterprise value (vs. 27.3 times for Pepsi), the stock is still value-priced.
The Motley Fool February 17, 2005 Jeremy MacNealy	Go With the Cash Flow! Garmin navigates through another successful year. The GPS technology leader's cash-producing machine is firing on all cylinders, but wise investors will want to track its EV/SFCF to navigate toward a better buying opportunity in the near future.
The Motley Fool February 17, 2005 Stephen D. Simpson	More Work to Do at Gentiva The country's largest home health-care provider has ample room to improve operating efficiency. Although Gentiva shouldn't be expected to post breathtaking growth, the valuation on these shares looks interesting.
The Motley Fool February 17, 2005 Stephen D. Simpson	Flat Panels Still Getting Flattened AU Optronics is one of the best panel makers around, but it's still in a highly competitive business. Investors need to do some investigation here.
The Motley Fool February 17, 2005 Karl Thiel	Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market.
The Motley Fool February 17, 2005 Nathan Parmelee	Should You Still Hold Starbucks? What are the company's growth prospects? In Starbucks' case the ROE is quite less than the P/E and the growth rate, but it is improving, and an ROE of 17% with almost no leverage is very good.
The Motley Fool February 17, 2005 Rich Duprey	Candela Does a Slow Burn Arbitrator rules against laser maker in royalty case. Already reeling from the lackluster sales of lasers that remove varicose veins, tattoos, and the like, Candela's stock plummeted another 10%.
The Motley Fool February 17, 2005 Stephen D. Simpson	Is Medtronic's Heartbeat Slowing? Will gradually decelerating growth lead to a multiple contraction on the medical device maker's stock?
The Motley Fool February 17, 2005 Richard Gibbons	First American Keeps One Shoe Earnings are down, but how bad is business really? Title insurer and mortgage-information provider First American Corporation's stock is up by 24% over the last few months.
<Older 5871-5880 Newer> Return to current articles.